Ars Pharmaceuticals Inc (SPRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 84,278 | 89,149 | 30 | 1,316 | 5,506 |
| Cost of Goods | 20,423 | 977 | N/A | N/A | N/A |
| Gross Profit | 63,855 | 88,172 | 30 | 1,316 | 5,506 |
| Operating Expenses | 243,726 | 92,232 | 67,550 | 36,832 | 24,960 |
| Operating Income | -179,448 | -3,083 | -67,520 | -35,516 | -19,454 |
| Other Income | 8,070 | 11,369 | 13,155 | 834 | -789 |
| Pre-tax Income | -171,378 | 8,286 | -54,365 | -34,682 | -20,243 |
| Income Tax | -80 | 288 | N/A | N/A | N/A |
| Net Income Continuous | -171,298 | 7,998 | -54,365 | -34,682 | -20,243 |
| Net Income | $-171,298 | $7,998 | $-54,365 | $-34,682 | $-20,243 |
| EPS Basic Total Ops | -1.74 | 0.08 | -0.57 | -0.87 | -0.70 |
| EPS Basic Continuous Ops | -1.74 | 0.08 | -0.57 | -0.87 | -0.70 |
| EPS Diluted Total Ops | -1.74 | 0.08 | -0.57 | -0.87 | -0.70 |
| EPS Diluted Continuous Ops | -1.74 | 0.08 | -0.57 | -0.87 | -0.70 |
| EPS Diluted Before Non-Recurring Items | -1.74 | 0.08 | -0.57 | -0.87 | -2.56 |
| EBITDA(a) | $-183,604 | $-10,258 | $-74,295 | $-35,197 | $-19,241 |